The pharmacogenetics of flibanserin involve key genes like CYP3A4 and CYP2C19 that influence its metabolism, affecting drug efficacy and safety, while ABCB1 gene variations alter its distribution and elimination, impacting drug exposure and response. These genetic interactions are crucial for understanding individual differences in treatment outcomes with flibanserin.